{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-270524","form_type":"8-K","ticker":"GYRE","cik":"0001124105","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2025-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.840492+00:00","generated_at":"2026-05-16T22:55:17.096406+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Gyre Therapeutics reports Q3 2025 net income of $5.9M, cuts FY revenue guidance to $115-118M","bullets":["Q3 revenue $30.6M (+20% YoY), net income $5.9M (doubled), adjusted net income $8.8M.","Full-year revenue guidance lowered to $115-118M from $118-128M due to Etorel rollout delays.","Nine-month 2025 revenue $79.4M, net income $11.2M vs $17.3M YoY; basic EPS $0.08.","Cash $80.3M as of Sept 30; completed Phase 3 pneumoconiosis trial enrollment (272 patients).","Hydronidone NDA in China progressing; US IND for MASH delayed to 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-270524","json":"https://secwatch.observer/filing/0001193125-25-270524.json","markdown":"https://secwatch.observer/filing/0001193125-25-270524.md","text":"https://secwatch.observer/filing/0001193125-25-270524.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124105/000119312525270524/0001193125-25-270524-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124105/000119312525270524/gyre-20251107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:55:17.096406+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}